A critique and systematic review of the clinical utility of hepatitis B core-related antigen

HBcAg 乙型肝炎表面抗原 医学 HBeAg 乙型肝炎 抗原 乙型肝炎病毒 免疫学 病毒学 计算生物学 生物 病毒
作者
Celina Adraneda,Yong Chuan Tan,Ee Jin Yeo,Guan Sen Kew,Atefeh Khakpoor,Seng Gee Lim
出处
期刊:Journal of Hepatology [Elsevier BV]
卷期号:78 (4): 731-741 被引量:42
标识
DOI:10.1016/j.jhep.2022.12.017
摘要

Highlights•The biological pathway of HBcrAg is distinct to that of HBsAg.•HBcrAg are translation products from precore and pregenomic RNA comprising HBV core antigen, p22cr and HBeAg.•HBeAg contributes >70% to HBcrAg in HBeAg-positive patients, but its components are non-quantifiable in HBeAg-negative patients.•HBcrAg exhibits variable clinical performance.AbstractBackground & AimsHepatitis B core-related antigen (HBcrAg) is a new biomarker for chronic hepatitis B (CHB) whose performance has not been critically or systematically appraised. Herein, we performed a systematic review to determine its clinical utility.MethodsWe evaluated the biological pathway of HBcrAg and performed a systematic review of PubMed for clinical trials, cohort studies, and case-control studies that evaluated the clinical utility of HBcrAg. The effectiveness of HBcrAg in predicting HBV-specific clinical events (e.g. HBeAg seroconversion, phases of CHB, HBsAg loss, treatment response, and relapse after stopping therapy) was examined using receiver-operating characteristic curves. The correlation coefficients of HBcrAg with HBV DNA, quantitative HBsAg (qHBsAg), HBV RNA, and cccDNA were summarised from published studies. Median values were used as estimates.ResultsHBcrAg consists of three precore/core protein products: HBcAg, HBeAg, and a 22 kDa precore protein. HBcrAg assays have been associated with false-positive rates of 9.3% and false-negative rates of between 12-35% for CHB. The new iTACT-HBcrAg is more sensitive but does not reduce the false-positive rate. A PubMed search found 248 papers on HBcrAg, of which 59 were suitable for analysis. The clinical performance of HBcrAg was evaluated using AUROC analyses, with median AUROCs of 0.860 for HBeAg seroconversion, 0.867 for predicting HBeAg(-) hepatitis, 0.645 for HBsAg loss, 0.757 for treatment response, and 0.688 for relapse after stopping therapy. The median correlation coefficient (r) was 0.630 with HBV DNA, 0.414 with qHBsAg, 0.619 with HBV RNA and 0.550 with cccDNA. Correlation decreased during antiviral therapy, but combined biomarkers improved performance.ConclusionsHBcrAg has a mixed performance and has a poor correlation with HBsAg loss and antiviral therapy, hence HBcrAg results should be interpreted with caution.Impact and implicationsHepatitis B core-related antigen (HBcrAg) has been used to assess management of patients with chronic hepatitis B (CHB) without a systematic and critical Sreview of its performance. Our finding that HBcrAg had a false-positive rate of 9% and a false-negative rate of 12-35% raises concerns, although larger studies are needed for validation. A systematic review showed that the performance of HBcrAg was variable depending on the CHB endpoint; it was excellent at predicting HBeAg seroconversion and HBeAg-negative chronic hepatitis (vs. chronic infection), which should be its main use, but it was poor for relapse after stopping antiviral therapy and for HBsAg loss. HBcrAg results should be interpreted with considerable caution, particularly by physicians, researchers, guideline committees and agencies that approve diagnostic tests.Graphical abstract
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
香蕉觅云的应助被谢富杰采纳,获得10
1秒前
1秒前
可可完成签到 ,获得积分10
1秒前
CipherSage的应助被muderder采纳,获得10
1秒前
2秒前
轻松峻熙发布了新的文献求助10
3秒前
科研通AI6.4的应助被ygy采纳,获得10
3秒前
贾贡献的应助被十二采纳,获得10
3秒前
迟宏珈发布了新的文献求助10
5秒前
文静迎南发布了新的文献求助10
6秒前
6秒前
6秒前
7秒前
CipherSage的应助被hyska采纳,获得10
7秒前
陈红安完成签到,获得积分10
8秒前
8秒前
巨小俊完成签到,获得积分10
9秒前
WT发布了新的文献求助10
10秒前
道天完成签到,获得积分10
11秒前
轻松峻熙完成签到,获得积分10
12秒前
谢富杰发布了新的文献求助10
12秒前
jiashan发布了新的文献求助30
12秒前
xh发布了新的文献求助10
13秒前
LeeStrife完成签到 ,获得积分10
13秒前
14秒前
14秒前
斯文败类的应助被科研通管家采纳,获得10
14秒前
无花果的应助被科研通管家采纳,获得10
14秒前
共享精神的应助被科研通管家采纳,获得10
14秒前
星辰大海的应助被科研通管家采纳,获得10
14秒前
NexusExplorer的应助被科研通管家采纳,获得10
14秒前
小二郎的应助被科研通管家采纳,获得10
14秒前
molihuakai的应助被科研通管家采纳,获得10
15秒前
15秒前
JamesPei的应助被科研通管家采纳,获得10
15秒前
Hello的应助被科研通管家采纳,获得10
15秒前
852的应助被科研通管家采纳,获得10
15秒前
16秒前
tib完成签到,获得积分10
16秒前
谢富杰完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8188394
求助须知:如何正确求助?哪些是违规求助? 9576268
关于积分的说明 21846207
捐赠科研通 7786486
什么是DOI,文献DOI怎么找? 3435317
关于科研通互助平台的介绍 2559618
邀请新用户注册赠送积分活动 2482322